BRPI0907363A2 - Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal - Google Patents
Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminalInfo
- Publication number
- BRPI0907363A2 BRPI0907363A2 BRPI0907363-9A BRPI0907363A BRPI0907363A2 BR PI0907363 A2 BRPI0907363 A2 BR PI0907363A2 BR PI0907363 A BRPI0907363 A BR PI0907363A BR PI0907363 A2 BRPI0907363 A2 BR PI0907363A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- proteins
- compositions
- methods
- terminal element
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ceramic Engineering (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3040908P | 2008-02-21 | 2008-02-21 | |
| PCT/US2009/034713 WO2009105671A2 (en) | 2008-02-21 | 2009-02-20 | Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907363A2 true BRPI0907363A2 (pt) | 2015-08-18 |
Family
ID=40986217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907363-9A BRPI0907363A2 (pt) | 2008-02-21 | 2009-02-20 | Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11260133B2 (pt) |
| EP (1) | EP2250278B1 (pt) |
| JP (1) | JP2011514160A (pt) |
| CN (1) | CN102016058A (pt) |
| AU (1) | AU2009215426B2 (pt) |
| BR (1) | BRPI0907363A2 (pt) |
| CA (1) | CA2713872A1 (pt) |
| ES (1) | ES2951646T3 (pt) |
| WO (1) | WO2009105671A2 (pt) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6850788B2 (en) | 2002-03-25 | 2005-02-01 | Masimo Corporation | Physiological measurement communications adapter |
| ES2368941T3 (es) | 2003-01-06 | 2011-11-23 | Angiochem Inc. | Angiopep-1, compuestos relacionados y utilizaciones correspondientes. |
| PL2233156T3 (pl) | 2005-07-15 | 2013-09-30 | Angiochem Inc | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2638823A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
| US9161696B2 (en) | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| AU2009234338B2 (en) | 2008-01-18 | 2014-07-24 | Burnham Institute For Medical Research | Methods and compositions related to internalizing RGD peptides |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
| WO2010069074A1 (en) | 2008-12-17 | 2010-06-24 | Universite Du Quebec A Montreal | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
| US8580749B2 (en) * | 2009-06-05 | 2013-11-12 | Cell Targeting, Inc. | Peptide-coated cell localization to diseased or damaged tissues and methods related thereto |
| BRPI1015424B1 (pt) | 2009-06-22 | 2022-01-18 | Burnham Institute For Medical Research | Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| US20120277158A1 (en) * | 2009-10-06 | 2012-11-01 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| US9006415B2 (en) | 2010-04-06 | 2015-04-14 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
| WO2011127405A1 (en) | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
| DK2699233T3 (en) | 2011-04-20 | 2017-07-10 | Univ Sydney | PARTICULAR MATERIAL AND CELLULAR TOXIN USED TO TREAT A SOLID TUMOR |
| WO2012166585A2 (en) | 2011-05-31 | 2012-12-06 | Airware, Inc. | Re-calibration of ab ndir gas sensors |
| US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
| EP3584799B1 (en) | 2011-10-13 | 2022-11-09 | Masimo Corporation | Medical monitoring hub |
| US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
| HK1201089A1 (en) | 2011-10-21 | 2015-08-21 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
| US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
| US10149616B2 (en) | 2012-02-09 | 2018-12-11 | Masimo Corporation | Wireless patient monitoring device |
| MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
| RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
| CA2871386A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| JP6203838B2 (ja) | 2012-06-27 | 2017-09-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用 |
| ES2723885T3 (es) | 2012-07-19 | 2019-09-03 | Daiichi Sankyo Co Ltd | Anticuerpos anti-Siglec-15 |
| RU2530592C2 (ru) * | 2012-07-20 | 2014-10-10 | Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) | Способ подавления роста опухолей |
| US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
| CN103720655B (zh) * | 2012-10-11 | 2016-05-25 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种d型多肽介导的靶向脂质体及其制备方法和应用 |
| CN103040755A (zh) * | 2012-12-27 | 2013-04-17 | 上海交通大学 | Aparpar多肽修饰的隐形脂质体及递药系统 |
| CN104072581B (zh) * | 2013-03-29 | 2017-02-15 | 复旦大学 | 具有脑肿瘤靶向和肿瘤组织穿透能力的d构型多肽及其基因递释系统 |
| US10832818B2 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Alarm notification system |
| US9908915B2 (en) | 2013-11-26 | 2018-03-06 | Yale University | Cell-penetrating compositions and methods using same |
| WO2015080980A2 (en) * | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
| JP6475835B2 (ja) | 2014-12-03 | 2019-02-27 | サムスン ライフ パブリック ウェルフェア ファウンデーションＳａｍｓｕｎｇ Ｌｉｆｅ Ｐｕｂｌｉｃ Ｗｅｌｆａｒｅ Ｆｏｕｎｄａｔｉｏｎ | ニューロピリン１（Ｎｅｕｒｏｐｉｌｉｎ １）に対する抗体およびその用途 |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| KR101551306B1 (ko) | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| WO2016172515A1 (en) * | 2015-04-23 | 2016-10-27 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| US10736518B2 (en) | 2015-08-31 | 2020-08-11 | Masimo Corporation | Systems and methods to monitor repositioning of a patient |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
| US11076777B2 (en) | 2016-10-13 | 2021-08-03 | Masimo Corporation | Systems and methods for monitoring orientation to reduce pressure ulcer formation |
| US10669313B2 (en) | 2016-11-25 | 2020-06-02 | Industry-Academic Cooperation Foundation, Yonsei University | Multitarget-directed bio-inorganic hybrid structure |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN109021067A (zh) * | 2017-06-09 | 2018-12-18 | 复旦大学 | 一种具有神经纤毛蛋白-1结合活性的多肽及其用途 |
| WO2019204368A1 (en) | 2018-04-19 | 2019-10-24 | Masimo Corporation | Mobile patient alarm display |
| EP3864869B1 (en) | 2018-10-12 | 2025-01-29 | Masimo Corporation | System for transmission of sensor data |
| US12495968B2 (en) | 2018-10-12 | 2025-12-16 | Masimo Corporation | System for transmission of sensor data using dual communication protocol |
| EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| US12351653B1 (en) | 2019-03-08 | 2025-07-08 | Lisata Therapeutics, Inc. | Pharmaceutical compositions comprising novel cyclic peptides |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US20210290184A1 (en) | 2020-03-20 | 2021-09-23 | Masimo Corporation | Remote patient management and monitoring systems and methods |
| US12005125B2 (en) | 2020-04-10 | 2024-06-11 | Mi2 Holdings LLC | Nanoparticles for use in photodynamic therapies and methods of making, evaluating and using the same |
| USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
| USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
| USD1072837S1 (en) | 2020-10-27 | 2025-04-29 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
| CN112426534B (zh) * | 2020-12-07 | 2021-09-24 | 南京林业大学 | 一种c端修饰肿瘤穿透肽rgerppr的铁蛋白纳米粒子、其制备方法及应用 |
| USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
| CA3227953A1 (en) | 2021-09-22 | 2023-03-30 | Masimo Corporation | Wearable device for noninvasive body temperature measurement |
| EP4432919A1 (en) | 2022-01-05 | 2024-09-25 | Masimo Corporation | Wrist and finger worn pulse oximetry system |
| CN114533698B (zh) * | 2022-02-15 | 2022-09-30 | 南京林业大学 | 一种修饰了d型肿瘤穿透肽的铁蛋白载药纳米粒的制备方法 |
| USD1048908S1 (en) | 2022-10-04 | 2024-10-29 | Masimo Corporation | Wearable sensor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US5262176A (en) | 1986-07-03 | 1993-11-16 | Advanced Magnetics, Inc. | Synthesis of polysaccharide covered superparamagnetic oxide colloids |
| US5569745A (en) * | 1994-02-25 | 1996-10-29 | Resolution Pharmaceuticals Inc. | Peptide-Chelator conjugates |
| US5662885A (en) * | 1994-07-22 | 1997-09-02 | Resolution Pharmaceuticals Inc. | Peptide derived radionuclide chelators |
| ES2309992T3 (es) * | 1995-10-20 | 2008-12-16 | University Of Nebraska Board Of Regents | Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno. |
| US6465427B1 (en) | 1996-07-12 | 2002-10-15 | Mcgill University | Compounds and methods for modulating cell adhesion |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| ATE391791T1 (de) | 2000-08-25 | 2008-04-15 | Aventis Pharma Inc | Membran penetrierende peptide und deren anwendungen |
| US7034109B2 (en) * | 2000-10-13 | 2006-04-25 | Christophe Bonny | Intracellular delivery of biological effectors |
| US20020193295A1 (en) | 2001-05-04 | 2002-12-19 | Emanuel Calenoff | Immunogenic peptides and uses thereof |
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| AU2004213749B2 (en) | 2003-01-31 | 2010-02-25 | Celldex Therapeutics, Inc. | Antibody vaccine conjugates and uses therefor |
| US20050085417A1 (en) * | 2003-10-16 | 2005-04-21 | Thomas Jefferson University | Compounds and methods for diagnostic imaging and therapy |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| ATE495197T1 (de) * | 2006-03-20 | 2011-01-15 | Cepep Iii Ab | Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel |
| AU2009234338B2 (en) | 2008-01-18 | 2014-07-24 | Burnham Institute For Medical Research | Methods and compositions related to internalizing RGD peptides |
| WO2010075540A1 (en) | 2008-12-23 | 2010-07-01 | Burnham Institute For Medical Research | Methods and compositions for synaphically-targeted treatment for cancer |
-
2009
- 2009-02-20 US US12/390,061 patent/US11260133B2/en active Active
- 2009-02-20 ES ES09711840T patent/ES2951646T3/es active Active
- 2009-02-20 BR BRPI0907363-9A patent/BRPI0907363A2/pt not_active Application Discontinuation
- 2009-02-20 WO PCT/US2009/034713 patent/WO2009105671A2/en not_active Ceased
- 2009-02-20 JP JP2010547800A patent/JP2011514160A/ja active Pending
- 2009-02-20 EP EP09711840.0A patent/EP2250278B1/en active Active
- 2009-02-20 CA CA2713872A patent/CA2713872A1/en not_active Abandoned
- 2009-02-20 CN CN2009801140567A patent/CN102016058A/zh active Pending
- 2009-02-20 AU AU2009215426A patent/AU2009215426B2/en active Active
-
2022
- 2022-02-25 US US17/681,380 patent/US20230173097A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009105671A3 (en) | 2009-10-15 |
| EP2250278B1 (en) | 2023-04-05 |
| ES2951646T3 (es) | 2023-10-24 |
| AU2009215426B2 (en) | 2015-06-11 |
| AU2009215426A1 (en) | 2009-08-27 |
| EP2250278A4 (en) | 2014-10-01 |
| US20230173097A1 (en) | 2023-06-08 |
| EP2250278A2 (en) | 2010-11-17 |
| WO2009105671A2 (en) | 2009-08-27 |
| US20090226372A1 (en) | 2009-09-10 |
| JP2011514160A (ja) | 2011-05-06 |
| CA2713872A1 (en) | 2009-08-27 |
| CN102016058A (zh) | 2011-04-13 |
| US11260133B2 (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907363A2 (pt) | Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal | |
| EP2093287A4 (en) | PEPTIDE BINDER IGG | |
| DK2046826T3 (da) | Exendin-fusionsproteiner | |
| EP1988927A4 (en) | Genetically engineered antibody-stress-protein-fusions | |
| EP2118122A4 (en) | NOVEL ANTIMICROBIAL PEPTIDES | |
| DK3118221T3 (da) | Proteiner | |
| BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
| DK2035447T3 (da) | Polypeptid | |
| ATE451392T1 (de) | Gegen amyloid-beta peptid gerichtete antikörper | |
| DK2390265T3 (da) | Insulinotropisk peptidderivat med modificeret N-terminal aminosyre | |
| BRPI0920749A2 (pt) | proteínas de ligação de antagonista multialvo cd86 | |
| HRP20170138T1 (hr) | Ponovno dobivanje proteina | |
| BRPI0911743A2 (pt) | "peptídeo" | |
| BRPI0819210A2 (pt) | Anticorpos de proteína g anti-rsv | |
| BRPI0818288A2 (pt) | Proteínas conjugadas e peptídeos. | |
| DK2061886T3 (da) | Små kationiske immunomodulerende peptider | |
| DK2307543T3 (da) | Forbedret proteinekspressionssystem | |
| SI2126093T1 (sl) | Izboljšanje priprave proteinov | |
| BRPI0906722A2 (pt) | Métodos e composições usando polipeptídeos de fusão klotho-fgf | |
| EP2161287A4 (en) | OPTIMIZED TACI FC FUSION PROTEINS | |
| EP2139906A4 (en) | aminophosphine | |
| BRPI0814971A2 (pt) | Proteína | |
| BRPI0819092A2 (pt) | Evolução direcionada usando proteínas que compreendem aminoácidos não naturais. | |
| BRPI0915367A2 (pt) | peptídeos e epítopos anti-p2x7 | |
| DK2001518T3 (da) | Cykliske natriuretiske peptidfremstillinger |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |